-+ 0.00%
-+ 0.00%
-+ 0.00%

Lingkang Pharmaceutical (603669.SH) subsidiary product Huperzine A for injection was selected and purchased by an inter-provincial alliance

Zhitongcaijing·08/12/2026 07:49:03
Listen to the news

Zhitong Finance App News, Lingkang Pharmaceutical (603669.SH) announced that Hainan Lingkang Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, participated in the bidding process led by Henan Province to carry out centralized volume procurement work for 34 drugs. According to the “34 Drugs Interprovincial Alliance Procurement Notice (8)” issued by the “34 Drugs Interprovincial Alliance Procurement Office” on August 11, 2026 on the Henan Pharmaceutical Centralized Procurement Platform, the subsidiary's product was selected for this procurement.

According to reports, the drug is suitable for benign memory disorders, improving patients' ability to point memory, associative learning, image recall, meaningless graphics, and portrait recall. It also improves memory impairment caused by dementia patients and organic brain lesions. In addition, this product is also used to treat myasthenia gravis. This selection is conducive to increasing the national market share of injectable Huperzine A (trade name: relisol) in the treatment of cognitive impairment and myasthenia gravis, and enhancing the company's brand influence.